↑ Grab this Headline Animator

Research and Markets Neurological Diseases and Psychiatric Illnesses...

May 13, 2005 -- Research and Markets (http://www.researchandmarkets.com/reports/c17318) has announced the addition of The Neurotechnology Industry 2005 - Strategic Investment and Market Analysis report of the Global Neurological Disease and Psychiatric Illness Markets to their offering.



Neurological diseases and psychiatric illnesses represent the largest and fastest growing unmet medical market: 1.5 billion people worldwide. Building on decades of brain research and the success of the Human Genome Project, neurotechnology companies hold the greatest potential for major scientific discoveries, commercial success and sustainable investment opportunities.



The neurotechnology industry includes companies researching, developing and marketing pharmaceuticals, biologics, medical devices, as well as diagnostic and surgical equipment for the treatment of neurological and psychiatric illnesses. This report has identified three sectors within the $100 billion industry: neuropharmaceuticals, neurodevices and neurodiagnostics. Neurotechnology companies face fundamentally different investment requirements, research and development challenges, regulatory milestones and social drivers that set them apart from other life science and health care companies.



"Neurotech companies are addressing the largest and fastest growing unmet medical market and the potential for high return investment has never been more compelling." - Mark Cochran, Managing Director, NeuroVentures Capital



Why this report

The Neurotechnology Industry 2005 is the first report to provide a unified market-based framework to help investors, companies, and governments easily quantify opportunities, determine risks and understand the dynamics of this rapidly growing market. This framework helps answer critical investment questions, such as:



- In what markets are neurodevices competing with neuropharmaceuticals

- What impact is neuroimaging having on drug development and disease diagnosis

- Who is investing in neurotechnology and what types of startups are getting funded

- How are public neurotech companies performing compared to other industries



Report Highlights

- Profiles of more than 300 public and private neurotech companies

- A comprehensive analysis of 15 major neurological diseases and psychiatric illnesses including Alzheimer's disease, attention deficit hyperactivity disorder, depression, anxiety, epilepsy, addiction, schizophrenia and pain

- The NeuroInsights' Neurotech Index: an investment benchmark that measures the stock performance of 30 publicly traded neurotechnology companies

- Profiles of the 10 most active neurotech venture capital firms, including investments by market segment

- Extensive discussion of the specific technological, demographic, regulatory, and intellectual property trends driving the global neurotech industry

- Analysis of the biological causes; current treatment options, emerging therapeutic strategies, and compounds in clinical trials by company, mechanism of action, and stage of development for each indication



"This is the first report to provide a comprehensive view of neurotechnology. It is a must read for any executive in the industry." - Rodney Pearlman, CEO, Saegis Pharmaceuticals



For more information visit http://www.researchandmarkets.com/reports/c17318



Laura Wood

Senior Manager

Research and Markets

e-mail protected from spam bots

Fax: +353 1 4100 980

↑ Grab this Headline Animator

---

This article has been robotically scanned and tagged by Prnewsnow with the following search tags. No human manipulation of these tags take place.
| Convention | Convention Strategy | |

---

4949 readers online...

, Local News